Drugmaker Gilead said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates, mostly in ...
Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.
Following the promising multicentre, international Purpose 1 and Purpose 2 clinical trials with lenacapavir for HIV ...
According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent ...
Dan O’Day drives Gilead's mission to end HIV worldwide, pioneering treatments like lenacapavir and championing global health ...
Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.
The New Republic on MSN2dOpinion
Big Pharma Is the Only Reason Anyone Still Dies From HIVWhile antiviral drugs to treat HIV had been approved a decade earlier, only five out of 33 million people who carried the ...
It's been called the closest the world has ever come to a vaccine against the AIDS virus. The twice-yearly shot was 100% ...
Hosted on MSN1d
Gilead Stock Surges 44.2% in 6 Months: Time to Buy or Sell?Biotech giant Gilead Sciences, Inc.’s GILD shares have risen 44.2% in the past six months compared with the industry’s growth of 1.1%. The stock has also outperformed the sector and the S&P 500. It ...
While Gilead has yet to bring a vaccine to market, that could be about to change after a phase 3 trial this year showed that ...
Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the company’s pivotal Phase 3 PURPOSE 2 trial evaluating twice-yearly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback